Top 6 Factors To Consider In Your Forecasting Strategy

Add bookmark
The increased market awareness for drugs targeting rare and life-threatening diseases has
coincided with a rise in the number of patients requesting early access to these medicines.

To meet the demand, an increasing number of pharmaceutical and biotechnology
companies are deciding to develop early access programmes. However, navigating the
nuances and complexities of these programmes has proven to be a resource draining task
and companies are looking to develop standards and streamline their processes.

[inlinead]

It is imperative for companies to have a comprehensive planning strategy before the
implementation of these programmes that needs to take a number of factors into
consideration.

Pharmaceutical specialists, Dr. Carlos R. Camozzi and Ramana Sonty spoke to Pharma IQ in regards to the top 6 factors to consider in an early access programme planning strategy.

  Have Your Say
Rate this feature and give us your feedback in the comments section below

Latest Webinars

Pharma IQ's Power List 2022: In conversation with pharma's top leaders

2022-10-18

02:00 PM - 03:00 PM BST

Join us to hear from the most influential people in pharma today, as voted for by you

A post-pandemic 3D view of the patient and supply journey

2022-06-01

04:30 PM - 05:30 PM CET

In this panel discussion with experts from 4G Clinical, THREAD Research and World Courier, learn how...

Discover how targeted radiotherapy induced toxicity can be identified with imaging

2022-04-28

01:00 PM - 02:00 PM EST

This Pharma IQ webinar with AIQ explores how AI-assisted analysis of radiological scans enhances the...

Recommended